Investigational Drug Information for Clemizole
✉ Email this page to a colleague
What is the drug development status for Clemizole?
Clemizole is an investigational drug.
There have been 4 clinical trials for Clemizole.
The most recent clinical trial was a Phase 1 trial, which was initiated on February 1st 2022.
The most common disease conditions in clinical trials are Syndrome, Epilepsies, Myoclonic, and Hepatitis. The leading clinical trial sponsors are Epygenix, Eiger BioPharmaceuticals, and GreenLight Clinical PTY LTD.
There are three hundred and forty US patents protecting this investigational drug and zero international patents.
Summary for Clemizole
| US Patents | 340 |
| International Patents | 3,871 |
| US Patent Applications | 1,380 |
| WIPO Patent Applications | 712 |
| Japanese Patent Applications | 235 |
| Clinical Trial Progress | Phase 1 (2022-02-01) |
| Vendors | 46 |
Recent Clinical Trials for Clemizole
| Title | Sponsor | Phase |
|---|---|---|
| EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children With Lennox Gastaut Syndrome. | Epygenix | Phase 2 |
| EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome | GreenLight Clinical PTY LTD | Phase 2 |
| EPX-100 (Clemizole Hydrochloride) as Add-on Therapy to Control Convulsive Seizures in Patients With Dravet Syndrome | Epygenix | Phase 2 |
Clinical Trial Summary for Clemizole
Top disease conditions for Clemizole
Top clinical trial sponsors for Clemizole
US Patents for Clemizole
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Clemizole | ⤷ Sign Up | Heterocyclic compound | Takeda Pharmaceutical Company Limited (Osaka, JP) | ⤷ Sign Up |
| Clemizole | ⤷ Sign Up | .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'-.beta.-C-substituted-2-modified-N.s- up.6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (Boston, MA) | ⤷ Sign Up |
| Clemizole | ⤷ Sign Up | Methods and compositions for treating infection | UNIVERSITY OF ROCHESTER (Rochester, NY) UNIVERSITY OF KANSAS (Lawrence, KS) | ⤷ Sign Up |
| Clemizole | ⤷ Sign Up | 1',4'-thio nucleosides for the treatment of HCV | IDENIX PHARMACEUTICALS LLC (Cambridge, MA) | ⤷ Sign Up |
| Clemizole | ⤷ Sign Up | .beta.-D-2'-deoxy-2'-.alpha.-fluoro-2'.beta.-C-substituted-2-modified-N.su- p.6-substituted purine nucleotides for HCV treatment | Atea Pharmaceuticals, Inc. (Boston, MA) | ⤷ Sign Up |
| Clemizole | ⤷ Sign Up | Benzimidazole derivatives | Enanta Pharmaceuticals, Inc. (Watertown, MA) | ⤷ Sign Up |
| Clemizole | ⤷ Sign Up | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections | EMORY UNIVERSITY (Atlanta, GA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Clemizole
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Clemizole | Canada | CA2961033 | 2034-09-11 | ⤷ Sign Up |
| Clemizole | European Patent Office | EP3192791 | 2034-09-11 | ⤷ Sign Up |
| Clemizole | Japan | JPWO2016039408 | 2034-09-11 | ⤷ Sign Up |
| Clemizole | World Intellectual Property Organization (WIPO) | WO2016039408 | 2034-09-11 | ⤷ Sign Up |
| Clemizole | Australia | AU2016229966 | 2035-03-06 | ⤷ Sign Up |
| Clemizole | Australia | AU2018282469 | 2035-03-06 | ⤷ Sign Up |
| Clemizole | Australia | AU2020203055 | 2035-03-06 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
